Dana Flanders
Stock Analyst at Guggenheim
(0.12)
# 4,466
Out of 5,124 analysts
9
Total ratings
16.67%
Success rate
-18.52%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dana Flanders
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VALN Valneva SE | Maintains: Buy | $17 → $15 | $9.49 | +58.06% | 1 | Mar 24, 2025 | |
| SCYX SCYNEXIS | Initiates: Buy | $25 | $0.77 | +3,151.40% | 1 | Jan 22, 2021 | |
| PCRX Pacira BioSciences | Initiates: Neutral | n/a | $21.00 | - | 1 | May 27, 2020 | |
| HRTX Heron Therapeutics | Initiates: Buy | $24 | $1.26 | +1,804.76% | 1 | May 27, 2020 | |
| COLL Collegium Pharmaceutical | Initiates: Neutral | n/a | $47.61 | - | 1 | May 27, 2020 | |
| LGND Ligand Pharmaceuticals | Initiates: Neutral | n/a | $190.44 | - | 2 | Mar 10, 2020 | |
| EBS Emergent BioSolutions | Upgrades: Buy | $60 → $75 | $10.92 | +586.81% | 2 | Nov 2, 2018 |
Valneva SE
Mar 24, 2025
Maintains: Buy
Price Target: $17 → $15
Current: $9.49
Upside: +58.06%
SCYNEXIS
Jan 22, 2021
Initiates: Buy
Price Target: $25
Current: $0.77
Upside: +3,151.40%
Pacira BioSciences
May 27, 2020
Initiates: Neutral
Price Target: n/a
Current: $21.00
Upside: -
Heron Therapeutics
May 27, 2020
Initiates: Buy
Price Target: $24
Current: $1.26
Upside: +1,804.76%
Collegium Pharmaceutical
May 27, 2020
Initiates: Neutral
Price Target: n/a
Current: $47.61
Upside: -
Ligand Pharmaceuticals
Mar 10, 2020
Initiates: Neutral
Price Target: n/a
Current: $190.44
Upside: -
Emergent BioSolutions
Nov 2, 2018
Upgrades: Buy
Price Target: $60 → $75
Current: $10.92
Upside: +586.81%